Successful intravenous regional block with low-dose tumor necrosis factor-α antibody infliximab for treatment of complex regional pain syndrome 1
Successful intravenous regional block with low-dose tumor necrosis factor-α antibody infliximab for treatment of complex regional pain syndrome 1
复制标题
DOI：
10.1213/01.ane.0000278867.24601.a0
复制
发表时间：
2007-10-01
影响因子：
5.7
通讯作者：
Karst, Matthias
中科院分区：
文献类型：
--
作者：
Bernateck, Michael;Rolke, Roman;Karst, Matthias
细胞因子，特别是肿瘤坏死因子-α，可能在复杂区域疼痛综合征1的机械性痛觉过敏和自主神经体征的调节中发挥重要作用。我们对1例具有复杂区域疼痛综合征1的典型临床体征(中度疼痛、浮肿、多汗、与对侧相比皮肤温度升高)的患者进行了小剂量肿瘤坏死因子-α抗体英夫利昔单抗的静脉区域阻断。在英夫利昔单抗治疗24小时后，临床变量有显著改善。在8周内几乎完全缓解，但感觉体征在6个月后才有所改善。未观察到不良反应。
Cytokines, particularly tumor necrosis factor-a, may play an important role in the mediation of mechanical hyperalgesia and autonomic signs in complex regional pain syndrome 1. We performed an IV regional block with low-dose administration of the tumor necrosis factor-alpha antibody, infliximab, in a patient with typical clinical signs of complex regional pain syndrome 1 (moderate pain, edema, hyperhidrosis, elevated skin temperature compared with the contralateral side). A significant improvement of clinical variables was observed 24 h after infliximab treatment. Almost complete remission was reached within 8 wk, but sensory signs improved only after 6 mo. No adverse events were observed.